Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby
RJ, Vitulli G, Bertolotti L, Read KD, Serabjit-Singh CJ. The systemic exposure of an
N-methyl-D-aspartate receptor antagonist is limited in mice by theP-glycoprotein
and breast cancer resistance protein efflux transporters. Drug Metab Dispos
2004;32:722–726.
Ramachandra M, Ambudkar SV, Gottesman MM, Pastan I, Hrycyna CA. Functional
characterization of a glycine 185-to-valine substitution in humanP-glycoprotein by
using a vaccinia-based transient expression system. Mol Biol Cell 1996;7:1485–1498.
Rao US. Mutation of glycine 185 to valine alters the ATPase function of the human P-
glycoprotein expressed in Sf9 cells. J Biol Chem 1995;270:6686–6690.
Robinson K, Johnston A, Walker S, Mulrow JP, McKenna WJ, Holt DW. The
digoxin–amiodarone interaction. Cardiovasc Drugs Ther 1989;3:25–28.
Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA. The
effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small
cell lung cancer. Cancer 1994;74:834–841.
Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain
by P-glycoprotein inhibition. Clin Pharmacol Ther 2000a;68:231–237.
Sadeque AJM, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to the brain
by P-glycoprotein inhibition. Clin Pharmacol Ther (St. Louis) 2000b;68:231–237.
Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS.
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used
in combination with amprenavir. Antimicrob Agents Chemother 2001;45:3663–3668.
Sarkadi B, Price EM, Boucher RC, German UA, Scarborough GA. Expression of the
human multidrug resistance cDNA insect cells generates a high activity drug-
stimulated membrane ATPase. J Biol Chem 1992;267:4854–4858.
Sarkadi B, Homolya L, Hollo Z. Assay and reagent kit for evaluation of multi-drug
resistance in cells; U.S. pp 17 pp., Cont.-in-part of U.S. 15,872,014, (Solvo
Biotechnology, Hung). 2001.
Sasongko L, Link JM, Muzi M, Mankoff DA, Yang X, Collier AC, Shoner SC,
Unadkat JD. Imaging P-glycoprotein transport activity at the human blood–brain
barrier with positron emission tomography. Clin Pharmacol Ther (New York, NY,
United States) 2005;77:503–514.
Satoh K, Shirabe S, Eguchi K, Yamauchi A, Kataoka Y, Niwa M, Nishida N,
Katamine S. Toxicity of quinacrine can be reduced by co-administration of
P-Glycoprotein inhibitor in sporadic creutzfeldt-jakob disease. Cell Mol Neurobiol
2004;24:873–875.
Scarborough GA. Drug-stimulated ATPase activity of the human P-glycoprotein. J
Bioenerg Biomembr 1995;27:37–41.
Schwarz UI, Gramatte T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W.
Unexpected effect of verapamil on oral bioavailability of the [beta]-blocker talinolol
in humans. Clin Pharmacol Ther 1999;65:283–290.
Schwarz UI, Gramatte T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor
erythromycin increases oral bioavailability of talinolol in humans. Int J Clin
Pharmacol Ther 2000;38:161–167.
Senior AE, al-Shawi MK, Urbatsch IL. ATP hydrolysis by multidrug resistance protein
from Chinese hamster ovary cells. J Bioenerg Biomembr 1995;27:31–36.
REFERENCES 197